To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
HT-0712 is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.
Additional recommended knowledge
Mechanism of action
HT-0712 appears to act as a PDE4-inhibitor, thereby increasing cAMP levels. When cAMP levels are increased in neurons, this may trigger activation of cAMP response element-binding proteins (CREB). CREBs are transcription factors involved in the formation of long-term memory.
The side effects of the drug are not yet fully known.
Middle-aged people, seniors, and possibly those suffering from dementia, who have a hard time remembering everyday events, can possibly benefit from this drug.
Performance enhancing use
Many students may be inclined to use nootropics for school and college life for exams and finals. This could also be an effective alternative or adjunctive to the use of caffeine as a study aid.
United States Patent 20040224316
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "HT-0712". A list of authors is available in Wikipedia.|